Abstract
Background
The presence of cutaneous nodules in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) receiving depot somatostatin analogs (SSAs) is a diagnostic challenge as differential diagnosis between injection site reactions and metastases is essential.
Objective
To characterize the clinical, radiological, cytological and histopathological features of subcutaneous nodules in patients with GEP-NETs treated with SSAs.
Materials and Methods
Retrospective, cross-sectional study of patients with GEP-NETs treated with SSAs in whom subcutaneous nodules were detected on routine abdominal CT scans. High resolution and color Doppler ultrasonography was performed. Those patients with inconclusive radiological studies went through fine-needle aspiration cytology (FNAC) and/or biopsy.
Results
Twelve patients (5 males, 7 females) were included (6 midgut carcinoid NETs, 6 pancreatic NETs). Three patients received intramuscular depot octreotide, 7 subcutaneous lanreotide, and 2 both treatments. CT scan findings were nonspecific. Sonography revealed a hyperechoic pattern in recent injections, and a hypoechoic pattern with a characteristic hyperechoic peripheral rim in long-term injections (more than 3 months after injection). On color Doppler sonography, nodules showed no signs of intralesional vascularity. Fine-needle aspiration cytology (FNAC) was performed in 5 patients, revealing a characteristic acellular proteinaceous material. Biopsy in 4 patients showed different reactional infiltrates around the acellular material.
Conclusions
High resolution and color Doppler ultrasonography may be very useful for the differential diagnosis of subcutaneous nodules in patients with GEP-NETs treated with SSAs. FNAC and a biopsy are useful tests for confirmation of the diagnosis in patients with inconclusive findings. We propose a management algorithm.
This article is protected by copyright. All rights reserved.
http://ift.tt/2rN5chZ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου